Synairgen has peer-reviewed data from the Company’s SG016 trial published in The Lancet Respiratory Medicine journal on 12 November 2020. The SG016 trial randomised 101 hospitalised COVID-19 patients to either SNG001, Synairgen’s inhaled formulation of interferon beta-1a, or placebo. Positive topline results from the trial were originally announced on 20 July 2020, with more detailed results of primary endpoint analyses disclosed in the Company’s 2020 Interim Results on 29 September 2020.
The full title of the publication is: “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial”, and can be accessed here.
SG016 Home Study Trial
For patients interested in participating in the SG016 home trial, please see the following link for more information:
Managed Access Program
For more information on Managed Access Program please click here.